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AbSTrACT
Acute exacerbations of chronic obstructive pulmonary 
disease (COPD) are associated with a significant 
mortality, health and economic burden. Their diagnosis, 
assessment and management remain suboptimal and 
unchanged for decades. Recent clinical and translational 
studies revealed that the significant heterogeneity in 
mechanisms and outcomes of exacerbations could 
be resolved by grouping them etiologically. This is 
anticipated to lead to a better understanding of 
the biological processes that underlie each type of 
exacerbation and to allow the introduction of precision 
medicine interventions that could improve outcomes. 
This review summarises novel data on the diagnosis, 
phenotyping, targeted treatment and prevention of 
COPD exacerbations.
InTroduCTIon
Acute exacerbations, punctuating the natural history 
of chronic obstructive pulmonary disease (COPD), 
are associated with significant mortality as well as 
health and socioeconomic burden.1–3 They are the 
main drivers of the poor outcomes of COPD, which 
is consequently ranked as a leading cause of death 
and disability globally.1–3 It is estimated that every 
year 22%–40% of all patients with COPD experi-
ence at least one moderate or severe exacerbation, 
while 9%–16% experience more than one.4 5 As 
a result, exacerbations are responsible for one in 
eight emergency hospital admissions in the UK; an 
enormous number, considering that the 3- month 
mortality rate of a hospitalised exacerbation exceeds 
15%.1 2 6 Patients experiencing frequent exacerba-
tions have worse quality of life,7 accelerated lung 
function decline8 and are at increased risk of future 
exacerbations, myocardial infarctions, cerebrovas-
cular events and mortality.9–12
With a definition, diagnostic criteria and treat-
ment strategies that remain insufficient and 
unchanged for decades,1–3 COPD exacerbations 
represent a major, unaddressed global health need. 
More specifically, their definition and diagnostic 
criteria are solely based on clinical characteris-
tics, which lack specificity. The same symptoms 
are present in stable COPD or they can result 
from other respiratory or cardiac diseases.13 14 
Therapeutically, exacerbations are approached as 
a single entity and treated uniformly with the 
administration of bronchodilators, systemic corti-
costeroids and commonly antibiotics.2 3 In reality, 
they are heterogeneous, characterised by diverging 
underlying mechanisms, outcomes and treatment 
needs. More specifically, only about 30%–50% 
of all exacerbations are associated with enhanced 
airway eosinophilic inflammation and appear 
to respond to systemic corticosteroids, whereas 
around 50% are triggered by bacterial infections 
and may respond to antibiotics.15–17 Finally, around 
30% that are triggered by viruses13 14 are currently 
not treated etiologically, despite the availability of 
potentially beneficial treatments. Importantly, the 
heterogeneity of COPD extends beyond exacer-
bations. Therefore, subgroups of patients may be 
predisposed to specific subtypes of exacerbations, 
suggesting a potential role of precision medicine in 
exacerbations prevention.
This review summarises novel data on the diag-
nosis, phenotyping, targeted treatment and preven-
tion of COPD exacerbations. A detailed description 
of the epidemiology, mechanisms, impact or 
outcomes of pneumonia, in patients with COPD, 
or of disease entities that could mimic COPD exac-
erbations was considered beyond the scope of this 
review.
CurrenT defInITIonS And dIAgnoSTIC 
CrITerIA
The development of an accurate definition and 
diagnostic criteria is impeded by the complexity 
and heterogeneity that characterises COPD exacer-
bations and our limited insight into their underlying 
mechanisms. As a result, all available definitions 
are solely based on clinical symptoms and have 
important limitations. An exacerbation is commonly 
described as an acute deterioration of the respira-
tory symptoms of patients with underlying COPD 
that results in additional therapy (table 1). These 
definitions have poor specificity, as numerous other 
respiratory or non- respiratory diseases may have a 
similar presentation.18 Their sensitivity is also poor, 
as patients who experience increased symptoms 
often do not seek medical advice and do not receive 
additional treatments.7 19 Most importantly, these 
definitions rely on patients’ and clinicians’ percep-
tions of the symptoms for diagnosis and severity 
assessment, without providing guidance for a stan-
dardised approach.
The Australian and New Zealand (COPD- X) and 
UK (National Institute for Health and Care Excel-
lence) guidelines also define exacerbations on the 
basis of symptoms, but administration of additional 
treatments is not a prerequisite.2 20 This approach 
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Table 1 Frequently used definitions and diagnostic criteria for COPD exacerbations
GOLD definition ‘Acute exacerbations are episodes of acute worsening of the respiratory symptoms of patients with COPD, that 
result in additional therapy1
Consensus conference 2002 (Rodriguez- Roisin) definition ‘In patients with underlying COPD, exacerbation is an acute sustained symptoms worsening from the stable state 
that is beyond normal day- to- day variation and necessitates a change in regular medications13
COPD- X (Australian and New Zealand Guidelines) ‘A COPD exacerbation is characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is 
beyond normal day- to- day variations, is acute in onset, and may warrant a change in regular medication or hospital 
admission20
NICE (UK Guidelines) ‘An exacerbation is a sustained worsening of the patient’s symptoms from their usual stable state which is beyond 
day- to- day variations and is acute in onset. Commonly reported symptoms are worsening breathlessness, cough, 
increased sputum production and change in sputum colour. The change in these symptoms often necessitates a 
change in medication2
Anthonisen criteria ‘In patients with underlying COPD, an exacerbation is an acute, sustained deterioration of at least two of the 
following symptoms: Increased sputum volume; increased sputum purulence; breathlessness’23
Modified Anthonisen criteria ‘In patients with underlying COPD, an exacerbation is an acute sustained deterioration of at least two of the 
following major symptoms or at least one major and one minor symptom. Major symptoms: Increased sputum 
volume; increased sputum purulence; breathlessness. Minor symptoms: cough; wheeze; nasal discharge; sore 
throat; pyrexia’24
EXACT criteria ‘The EXACT patient- reported diary is a patient- reported outcome measure developed to identify COPD 
exacerbations, by quantifying daily the intensity of the following symptoms: congestion, cough, sputum production, 
sputum thickness, chest discomfort, chest tightness, and breathlessness. An exacerbation is defined by an increase 
of at least 12 points for two consecutive days or an increase of at least 9 points for at least three consecutive 
days’25
COPD, chronic obstructive pulmonary disease; EXACT, The Exacerbations of Chronic Pulmonary Disease Tool; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NICE, 
National Institute for Health and Care Excellence; NICE, The National Institute for Health and Care Excellence.
may be more sensitive, but at the expense of an even lower 
specificity.
Clinical research studies often use more strict diagnostic 
criteria, aiming to select a more homogeneous group of events.21 22 
In the 1980s, Anthonisen et al described exacerbations as acute, 
sustained deterioration of at least two symptoms of sputum 
volume, sputum purulence and breathlessness.23 These criteria 
were considered less sensitive to non- infective events and for this 
reason, a modified version was proposed, describing exacerba-
tions as an acute deterioration of at least one of the aforemen-
tioned major criteria and either a second major or one minor 
criterion(cough, wheeze, nasal discharge, sore throat or fever).24 
Daily monitoring of symptom intensity compared with baseline 
has also been suggested as a more accurate method to capture all 
exacerbations. Examples include the Exacerbations of Chronic 
Pulmonary Disease Tool (EXACT) questionnaire or the London 
COPD diary cards.7 25 While daily monitoring is currently used 
mainly in clinical research, the development of effective mobile 
applications could facilitate their introduction to clinical care.26
The characteristics and outcomes of the episodes that are 
captured when using each of these definitions or diagnostic 
criteria for exacerbations are very different. The modified 
Anthonisen criteria used in the London COPD cohort study led 
to the identification of twice as many exacerbations compared 
with those leading to healthcare utilisation by patients.27 Unfor-
tunately, it is still unclear which of these episodes are associ-
ated with increased risk of death, disability, poor quality of life, 
disease progression or cardiovascular events, and require more 
aggressive management. Thus, there is an urgent need for accu-
rate diagnostic and prognostic biomarkers to complement clin-
ical characteristics.
dIAgnoSTIC And prognoSTIC bIomArkerS
The National Institutes of Health (NIH) working group defined 
a biomarker or biological marker as ‘a characteristic that is 
objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention’.28 In the context of 
COPD exacerbations, the role of biomarkers encompasses 
different areas. They can be applied as a diagnostic tool for early 
detection of events, as staging tools to classify disease severity 
and/or identify important subgroups, as prognostic tools to 
predict clinically important outcomes and, probably most impor-
tantly as therapeutic tools to identify treatment indications and 
monitor response. Ideally, a biomarker for COPD exacerbations 
is mechanistically linked to the acute burst of airway inflamma-
tion which it detects with both high negative and high positive 
predictive value. It should be amendable to existing therapeutic 
interventions (treatable trait)29 and serve as a surrogate endpoint 
for prognostic purposes. Moreover, for broad clinical implemen-
tation, a biomarker should be obtained non- invasively, highly 
reproducible and preferentially available at low cost. As cardiac 
troponin T covers most of these demands in the context of 
acute myocardial infarction, for many years the challenge within 
COPD exacerbations has been in searching for an equally well- 
performing biomarker. However, it seems generally accepted 
that due to the heterogeneity of exacerbations, such a ‘global’ 
marker most likely does not exist.30 31
From the Evaluation of COPD Logitudinally to Identify 
Predictice Surrogate End- points (ECLIPSE) study, following 
2138 patients with COPD for 3 years, it was demonstrated 
that number of previous exacerbations, history of heartburn or 
reflux, forced expiratory volume in 1 s (FEV1) and quality of life 
were the most important determinants for future exacerbation 
risk prediction.9 Importantly, several blood biomarkers, such 
as C- reactive protein (CRP), fibrinogen, surfactant, cytokines, 
white blood cell differentiation, did not significantly improve 
risk prediction when history of exacerbations were adjusted for. 
A more recent extensive analysis on 119 blood biomarkers from 
the COPD Genetic Epidemiology study (COPDGene) and the 
Subpopulations and Intermediate Outcome Measures in COPD 
study (SPIROMICS) cohort confirmed that blood markers added 
little to the predictive value of clinical covariates for exacerba-
tions.32 An accompanying editorial even stated that the search for 
a single blood biomarker of exacerbation frequency had come to 
an end.33 It is noteworthy that the majority of participants in 
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figure 1 Characterisation and aetiological treatment of acute 
exacerbations of chronic obstructive pulmonary disease.
these studies came from secondary respiratory centres. In 6574 
subjects with COPD identified in general population studies in 
Copenhagen, simultaneous elevated levels of CRP, fibrinogen 
and total white blood cell count associated with higher risk for 
exacerbations, particularly in the clinical subgroup of patients at 
risk because of exacerbation history or poor FEV1.
34 Moreover, 
an accurate imaging biomarker was identified in an analysis from 
the COPDGene and ECLIPSE studies. A ratio of the diameter 
of the pulmonary artery to that of the aorta exceeding one and 
suggesting pulmonary hypertension was independently asso-
ciated with a threefold increase in the risk of exacerbations.35 
Physiological markers, such as increased respiratory impedance, 
were also predictive of future exacerbations.36
When focussing on the role of biomarkers to detect an ongoing 
acute exacerbation, Noell et al performed a multilevel network 
analysis including blood and sputum biomarkers on top of a 
detailed clinical characterisation.37 Unsurprisingly, they found 
that a combination of elevated CRP, neutrophils and increased 
levels of breathlessness was the best panel to discriminate between 
acute exacerbation and stable state. More importantly, another 
group evaluating the association of exacerbations with lung 
tissue injury, demonstrated altered circulatory levels of several 
respiratory extracellular matrix turnover biomarkers with diag-
nostic potential, in two independent patient cohorts.38 39 These 
biomarkers, being mechanistically linked to lung tissue injury, 
may be able to identify those events that are associated with future 
risk of poor outcomes, although this will need to be further eval-
uated. Such patterns of biomarkers of lung tissue injury have the 
potential to revolutionise the management of exacerbations the 
same way that troponin revolutionised the management of acute 
cardiac chest pain by differentiating myocardial infarctions from 
simple episodes of angina.40 Non- circulatory biomarkers have 
also been evaluated. Interestingly, exploratory studies identified 
differences in the exhaled breath profiles of patients with COPD 
during stable disease state versus exacerbations, suggesting a 
potential diagnostic role.41 42Many individual clinical features 
and scorings based on multiple, independent and relevant clin-
ical characteristics have been validated to predict outcomes of 
the acute event. Dependent on the outcome (within hospital 
mortality, 90- day post- onset mortality, readmission or time to 
the subsequent event) different clinical features will dominate 
in the prediction tool. Unfortunately, the European COPD audit 
comprising clinical data of more than 13 000 hospital admissions 
for exacerbations was not able to evaluate the added value of 
blood or sputum biomarkers on prognostication.43 Neverthe-
less, some single- centre studies highlight the important prog-
nostic value of eosinopenia, acidaemia44 and the cardiac blood 
markers troponin T and N- terminal(NT)- pro- Brain Natriuretic 
Peptide (NT- proBNP) when corrected for clinical covariates.45 46 
Several circulatory biomarkers of extracellular matrix turnover 
were found more deranged in severe, compared with moderate 
exacerbations, suggesting a potential prognostic value.39 Neural 
respiratory drive, a physiological marker, also appears predictive 
of treatment response and the long- term outcomes of exacerba-
tions.47 48 For a more comprehensive insight on the prognostica-
tion role of blood or sputum markers measured at the onset of 
exacerbations, discharge or end of medical intervention, larger 
multicentre studies are needed.
A possible way of facilitating biomarker discovery in COPD 
exacerbations could be to better identify and characterise the 
subtypes of exacerbations. Classification of exacerbations by 
their causative agent, such as bacterial infections, viral infections 
or enhanced airway inflammation, appears to be the most prom-
ising (figure 1).15 17 With an unbiased cluster analysis based on 
blood and sputum biomarkers, Bafadhel and colleagues demon-
strated exacerbations of the same aetiology (bacteria, viruses, 
enhanced eosinophilic inflammation or pauci- inflammatory) 
exert similar inflammatory patterns. In line with these studies, 
several groups explore the mechanisms and potential biomarkers 
of each of these types of exacerbations. Exacerbations triggered 
by bacteria, viruses or enhanced eosinophilic inflammation are 
discussed below.
bACTerIA And Copd exACerbATIonS
Bacteria are frequently identified in sputum culture in over 50% 
of exacerbations, especially during winter months, but high 
detection rates (>25%) also occur during stable disease.15 17 49–53 
Therefore, the identification of bacteria during an exacerbation 
cannot establish bacterial aetiology. In the absence of experi-
mental bacterial challenge studies in COPD, it remains uncon-
firmed whether bacteria can directly trigger exacerbations. The 
various mechanisms regarding how bacteria might trigger exac-
erbations are discussed below.
Studies have examined whether an increase in lung bacterial 
loads could induce exacerbation. Several large observational 
studies have reported increased bacterial loads at exacerbation 
compared with stable state; Rossell et al confirmed these find-
ings using protected brush speciments.52 Conversely, Sethi et al 
showed no difference in sputum concentrations of potentially 
pathogenic bacteria Haemophilus influenzae and Moraxella 
catarrhalis from stability to exacerbation and also showed 
inverse relationships between concentrations of Streptococcus 
pneumoniae and Haemophilus parainfluenzae with exacerbation 
occurrence.54 Thus, evidence to support outgrowth of specific 
pathogens triggering exacerbation remains limited.
An alternative concept is that acquisition of a new strain of 
bacterium could be a potential mechanism of COPD exacerba-
tion. Sethi et al used molecular typing to show that detection 
of a new, previously unencountered, bacterial strain was asso-
ciated with a significantly increased risk of exacerbation (rela-
tive risk 2.15; 1.83–2.53; p<0.001).55 Specifically, acquisition 
of new strains of H. influenzae, M. catarrhalis and S. pneumo-
niae was all shown to be significantly associated with increased 
risk of exacerbation.55 Importantly, similar associations were 
not observed when considering cultured bacteria without 
strain information in this study. In a follow- up study from this 
group, clinical and inflammatory responses in patients with new 
bacterial strain acquisition were evaluated.56 New strain exac-
erbations were characterised by greater symptom scores, had a 
greater increase in airway inflammation including augmentation 
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of the pro- inflammatory cytokine tumour necrosis factor-α and 
neutrophil elastase when compared with pathogen- negative 
exacerbations. These data were supported in a separate study 
by Chin et al, where strains of H. influenzae isolated during 
exacerbations induced greater inflammatory responses in human 
airway epithelial cell cultures and mouse infection models than 
strains isolated during clinical stability.57
Lung microbiota alterations have also been incriminated as 
potential causes of exacerbations. Modern molecular sequencing 
techniques have revealed that the healthy respiratory tract is 
colonised by microbiota consisting of complex bacterial commu-
nities.58 The microbiota in COPD is broadly characterised by 
an outgrowth of the Proteobacteria phylum and an increase in 
proportion of Streptococci and Staphylococci within the Firmic-
utes phylum58–60 Our knowledge of the dynamic shifts that occur 
within the lung microbiota during exacerbations is limited but 
recent studies have shed some light on this topic.61–64 Mayhew 
et al showed in the Acute Exacerbations and Respiratory Infec-
tions in COPD (AERIS) study that expansion of Proteobacteria 
(Moraxella) within the microbiota are observed at exacerba-
tion.63 Wang et al reported data from the COPDMAP study 
showing that microbial dysbiosis was present in 41% of exac-
erbations and was associated with increased acute FEV1 decline 
and increased COPD Assessment Test (CAT) scores.62 Further 
studies are needed to understand if and how shifts in the micro-
biota may lead to exacerbation and to understand the immune 
mechanisms responsible for these changes.
An alternative mechanism through which bacteria could 
trigger COPD exacerbation is following an initial virus infec-
tion. Studies of naturally occurring and experimentally induced 
exacerbations have demonstrated the occurrence of secondary 
bacterial infections following an initial rhinovirus infection64–66 
Neutrophil elastase- mediated cleavage and reduction of the anti-
microbial peptide Secretory Leukocyte Protease Inhibitor (SLPI) 
is believed to be important mechanistically65 and may be wors-
ened by chronic use of inhaled corticosteroids (ICSs).67
Despite the fact that the role of bacterial infection as a trigger 
for exacerbations of COPD is unconfirmed, antibiotic use 
remains widespread:>80% in secondary care and around 50% 
in primary care.68 69 The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) documents state that antibiotic use 
for COPD exacerbations is category B evidence (few randomised 
studies exist, small in size and heterogeneous populations).1 In 
particular, there are very few placebo- controlled trials. A major 
limitation with current approaches to exacerbation management 
is the lack of a reliable rapid biomarker of bacterial infection 
to facilitate more targeted antibiotic prescribing. Older methods 
such as the Anthonisen criteria (symptom complex to identify 
patients with greater likelihood of bacterial infection)23 are likely 
to be insensitive. Newer biomarkers are currently being clinically 
validated. The use of CRP to guide antibiotics administration has 
been evaluated in two recent randomised controlled trials (RCTs). 
The C- Reactive Protein Testing to Guide Antibiotic Prescribing 
for COPD Exacerbations (PACE) study involved 653 patients 
with moderate exacerbations,70 while the CRP- guided antibiotic 
treatment in acute exacerbations of COPD in hospital admis-
sions (CATCH) trial randomised 101 patients with severe exac-
erbations.71 In both trials, use of CRP led to a modest decrease in 
antibiotics use (20.4% and 15.5% absolute decrease), without any 
adverse impact on the clinical outcomes. Procalcitonin- guided 
antibiotic administration has been evaluated in several RCTs. A 
recent meta- analysis including data from eight RCTs and 1062 
patients suggested procalcitonin can decrease the proportion of 
patients with severe COPD exacerbations receiving antibiotics 
by 45% (absolute decrease of 28%), without adversely affecting 
clinical outcomes.16 It concluded that larger RCTs are needed 
to confirm these findings.16 Another RCT tested the hypothesis 
that knowledge of respiratory viruses screening findings could 
help clinicians reduce antibiotic administration.72 Not unexpect-
edly, this RCT did not show any evidence of reduction in antibi-
otics use. This biomarker is neither sensitive, since antibiotics are 
required in cases where bacteria and viruses coexist, nor specific, 
since exacerbations triggered by eosinophilic inflammation may 
also test negative for viruses.
reSpIrATory vIruSeS And Copd exACerbATIonS
Respiratory viruses are identified in 30%–50% of all COPD exac-
erbations.15 17 66 73 However, they are also identified in >10% of 
patients during stable disease state, at any given time.66 74 75 Most 
frequently detected viruses in COPD include rhinovirus, influ-
enza and respiratory syncytial virus (RSV).15 17 74 75 In contrast 
to the uncertainty on how bacteria trigger exacerbations, experi-
mental viral challenge studies have confirmed a direct causal link 
between viral infections and COPD exacerbations.76 77
Limited information is available about the impact of the pres-
ence of respiratory viruses on the outcomes of COPD. Presence 
of viruses is associated with worse clinical outcomes both in 
stable COPD and in acute exacerbations.74 75 In the East London 
COPD cohort, the presence of any virus during stable disease 
state was associated with 60% more frequent exacerbations, 
while their presence during exacerbations was associated with 
delayed recovery and a higher symptoms burden.75 However, 
another retrospective cohort analysis found a lower mortality rate 
in exacerbations associated with respiratory viruses compared 
with those testing positive for bacteria either based on culture 
or PCR of sputum, endotracheal aspirates or bronchoalveolar 
lavage.78 Different respiratory viruses may have different effects 
on the immune responses and thus distinct clinical outcomes, 
but most studies evaluate the presence of all viruses and data are 
scarce on the differential clinical impact of specific virus types. 
Occasionally, both bacteria and viruses are identified in exacer-
bations and their coexistence is associated with a longer length 
of hospital stay and a higher symptom burden.79
As COPD exacerbations triggered by viruses are character-
ised by more prolonged and burdensome symptoms, antiviral 
vaccines and treatments may be beneficial. Several RCTs and 
large real- life studies have demonstrated that influenza vacci-
nation is highly effective in reducing the frequency of COPD 
exacerbations.80 81 Neuraminidase inhibitors are of proven 
benefit for the treatment of influenza; however, in clinical prac-
tice, influenza is underdiagnosed in exacerbations.82 In contrast 
to healthy adults, use of commercially available antivirals for 
exacerbations triggered by other viruses (such as RSV)83 might 
be beneficial, since viral infections are associated with a higher 
burden in patients with COPD. However, their use in RCTs or 
clinical practice is impeded by the absence of accurate diagnostic 
biomarkers for exacerbations triggered by viruses.
While modern molecular techniques allow rapid identifica-
tion of the presence of respiratory viruses possible, this cannot 
establish viral aetiology of an exacerbation, since respiratory 
viruses are often present in stable COPD. An accurate biomarker 
that can accurately confirm viral aetiology of exacerbations is 
still lacking. Symptoms of upper respiratory tract infection or 
common cold may concur or precede exacerbations associated 
with viruses; however, diagnostic accuracy of this approach is 
limited.66 73 Serum IP-10 is raised in rhinovirus- positive exacer-
bations and strongly correlates with viral load.84 Viral load also 
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correlates with the severity of upper respiratory tract symptoms.84 
This is consistent with the natural history of acute respiratory 
viral infections in healthy subjects where initial replication in the 
respiratory tract leads to high viral load that peaks early in the 
course of disease, and may be followed by a prolonged period of 
viral shedding and lower viral loads.85 A similar pattern was also 
observed in experimental viral challenge studies in patients with 
COPD.76 77 Therefore, a surrogate marker of viral load could be 
useful diagnostically.
exACerbATIonS ChArACTerISed by enhAnCed 
eoSInophIlIC InflAmmATIon In The AIrwAyS
Airway inflammation in COPD includes the presence of various 
inflammatory cells such as neutrophils, CD8 +T lymphocytes, 
mast cells, eosinophils and macrophages.86 Until recently, 
COPD was considered a primarily neutrophil- mediated inflam-
matory disease. However, 20%–40% of patients with COPD 
have been found to have eosinophilic airway inflammation, 
both during stable disease state and exacerbations, even after 
excluding subjects with coexisting asthma.15 87 88 Interestingly, 
these patients exhibit better response to corticosteroid therapy 
in both stable COPD and during exacerbations.89–91 Blood eosin-
ophil count correlates reasonably well with eosinophil levels in 
sputum and airways and could be used as a surrogate measure of 
airway eosinophilia in COPD.88
In stable COPD, a higher blood eosinophil count is associated 
with an increased risk of future exacerbations,92 93 especially 
eosinophilic exacerbations.94 It is also predictive of treatment 
response (exacerbation reduction) to ICSs.87 95
COPD exacerbations characterised by enhanced airway 
eosinophilic inflammation are generally milder, as they are 
associated with lower mortality44 and shorter length of hospital 
stay.96 Bacterial infections are rarely present, while the pres-
ence of viral infection in exacerbations characterised by airway 
eosinophilia remains controversial.15 92 97 Higher blood eosino-
phil count during exacerbations is predictive of clinical response 
to oral corticosteroids.90 91 An RCT evaluating 166 mostly 
moderate severity exacerbations demonstrated the safety of 
withholding systemic corticosteroids in those characterised by a 
blood eosinophil count of less than 2% of total white cell count 
at baseline.90 While studies evaluating stable COPD suggested 
a degree of variability in blood eosinophils over time,98 this 
did not appear to limit the results of this trial. However, use of 
additional eosinophil measurements to guide the administra-
tion of systemic corticosteroids may be preferable, especially 
for severe exacerbations. Indeed, the Corticosteroid Reduction 
in COPD (CORTICO- COP) trial demonstrated non- inferiority 
of a treatment protocol where daily eosinophil measurements 
were used to guide daily administration of systemic steroids for 
severe COPD exacerbations, compared with standard care.91 99 
Based on this treatment protocol, which reduced cumulative 
prednisolone dose by 60%, corticosteroids were administered 
for a maximum of up to 5 days—on days when the blood 
eosinophil count was at least 0.3×109 cells/L. In line with 
these RCTs, a post- hoc analysis of three clinical trials, using 
blood eosinophils to direct oral corticosteroid therapy for 
the treatment of COPD exacerbations, found increased treat-
ment failure rates in patients with a blood eosinophil count 
≥2% who did not receive prednisolone compared with patients 
who did (66% vs 11%).100 On the contrary, increased harm 
was observed in patients with blood eosinophil count of <2%, 
when treated with prednisolone. There remains an ongoing 
debate as to the appropriate eosinophil count threshold for 
risk stratification. This has been investigated in more depth in 
studies evaluating treatment of stable COPD with ICS. Several 
studies have reported a 2% eosinophil threshold, while others 
have focused on the absolute eosinophil counts. Based on data 
from the COPDGene and ECLIPSE studies, a consistent linear 
relationship between eosinophil counts and exacerbation risk 
was seen. In the same study, multivariable logistic regression 
models using different eosinophil count cut- offs found that a 
threshold of 0.3×109 cells/L was associated with the greatest 
sensitivity (72.6 %) and specificity (66.0%) for identifying a 
risk of self- reported exacerbation of at least one event.101 The 
Copenhagen Lung Study showed an increase in exacerbations 
when blood eosinophilia count was above 0.34×109 cells/l94. 
Overall, blood eosinophils represent a continuous biomarker 
and a threshold with perfect performance characteristics is very 
unlikely to be found.
Better characterisation of the eosinophilic COPD phenotype 
may allow the introduction of more targeted treatment strat-
egies. This could limit the use of corticosteroids in a patient 
group with a low eosinophil count, an already vulnerable 
patient group.
preCISIon medICIne In The prevenTIon of 
exACerbATIonS
Prevention of exacerbations is a crucial therapeutic aim in stable 
COPD. Most available treatments address this to some extent, 
as demonstrated by RCTs of unselected patients with COPD and 
frequent exacerbations (summarised in the ERS/ATS guideline 
on the prevention of COPD exacerbations102 and the GOLD 
document.1
More personalised preventive approaches have not been tested 
yet. However, there is emerging evidence suggesting a potential 
role for such interventions. Characteristically, a recent report 
from the AERIS longitudinal cohort suggested that patients 
tend to experience either recurrent bacterial or recurrent eosin-
ophilic exacerbations.63 This group of patients might benefit 
from different preventive strategies. Consistently, in the Study to 
understand mortality and morbidity in COPD (SUMMIT) trial, 
the addition of an ICS (fluticasone furoate) led to a reduction in 
the frequency of exacerbations that were treated with systemic 
corticosteroids alone or with both antibiotics and systemic 
corticosteroids, with treatment being decided by the respon-
sible clinician.103 On the other hand, fluticasone led to a 12% 
increase in the frequency of exacerbations treated by antibiotics 
alone, compared with placebo. Data from the Effect of Inda-
caterol Glycopyrronium vs. Fluticasone Salmeterol on COPD 
exacerbations (FLAME) trial showed that the combination of 
a long- acting beta- agonist (indacaterol) with a long- acting anti-
muscarinic (glycopyrronium), compared with the combination 
of a long- acting beta- agonist (salmeterol) and an ICS (flutica-
sone propionate) significantly reduced the rate of moderate or 
severe exacerbations treated with antibiotics and those treated 
with antibiotics and systemic corticosteroids.104 The impact of 
the two interventions on exacerbations treated with systemic 
corticosteroids alone was comparable.
These observations suggest that long- acting bronchodilators 
are effective in preventing all subtypes of exacerbations. On the 
other hand, ICSs may be more effective for people with frequent 
eosinophilic exacerbations but should be avoided in patients 
experiencing recurrent bacterial exacerbations. Further research 
is needed to validate these findings and evaluate the role of 
different medications in the exacerbations’ defined patient 
groups.
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The vISIon: perSonAlISed mAnAgemenT of Copd 
exACerbATIonS
Assessment, management and prevention of exacerbations are 
anticipated to change significantly in the future. As described, the 
heterogeneity in mechanisms and outcomes of COPD exacerba-
tions can be resolved by grouping them aetiologically. Therefore, 
the main challenge to tackle is the development and validation 
of accurate biomarkers for early characterisation of the different 
types of exacerbations, which clearly extend beyond bacterial, 
viral and eosinophilic exacerbations that were discussed in 
detail here (figure 1). Such biomarkers could facilitate optimi-
sation of exacerbation management and development of novel, 
targeted treatments. Since most exacerbations are addressed in 
primary care, the selected biomarkers will need to be measur-
able rapidly, near the patient, and simple, to facilitate implemen-
tation in primary care. RCTs focusing on the management of 
specific exacerbation subgroups are needed. These are likely to 
improve the clinical outcomes of exacerbations, but also COPD 
in general.
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